戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                                      Through proof and simulation, we determine which coding schemes
2 hat digestibility generally increased during proofing and decreased during baking.
3     We first discuss two kinds of 'evolution-proof' antibiotic.
4 stem relies not only on theoretical security proofs, but also on how closely the physical system matc
5                                          The proofs exploit two recent approaches.
6  of the Illumina array version and is future proof for newer Illumina array designs.
7 of this study is the lack of histopathologic proof in most patients.
8 eters that were monitored included alcoholic proof, l-lactic acid content, glucose+fructose and aceti
9 tem's stiffness k and the gap x2 between the proof mass and reverse constraint blocks have significan
10 hat in the designed inertial microswitch the proof mass weight G, the whole system's stiffness k and
11  trap placement, targeted cleaning, allergen-proof mattress and pillow encasements, and portable air
12                   This study provides direct proof of a biologically mediated mechanism of volatile e
13 rface of the eye is also a mucosal site, but proof of a living, resident ocular microbiome remains el
14  This is the first structural and functional proof of a supramolecular ligand targeting a PPI interfa
15                       Here, we give a simple proof of a theorem: In generalized KS theory (GKS), the
16 been challenging to demonstrate experimental proof of causality of these risk alleles for renal disea
17                                   We provide proof of concept data by profiling 60 drugs on 68 acute
18 er, these new findings provide a preclinical proof of concept defining C1572 as a promising therapeut
19                                         This proof of concept developed herein holds immense promise
20 e-shaped gold particles were fabricated as a proof of concept experiment.
21 riptional complex and provides rationale and proof of concept for a combinatorial therapeutic attack
22                         This work provides a proof of concept for a general strategy to use nanohoops
23             Therefore, DPM-1001 represents a proof of concept for a new approach to therapeutic inter
24              Our studies offer a preclinical proof of concept for a strategy of cotargeting the EGFR
25                                           As proof of concept for anti-TRBC immunotherapy, we develop
26 gnosis in TNBC, and they offer a preclinical proof of concept for combining CDK7 and BCL-2/BCL-XL inh
27              Our results offer a preclinical proof of concept for CRLX101 as a modality to improve th
28 ollectively, our results offer a preclinical proof of concept for ERK5 as a target to enhance T-cell
29       Overall, our results offer preclinical proof of concept for H3B-6527 as a candidate therapeutic
30                            Our results offer proof of concept for identifying novel cancer risk loci
31 ificance: These findings offer a preclinical proof of concept for immunotherapeutic targeting of an e
32             Our findings offer a preclinical proof of concept for immunotherapeutic targeting of TEM8
33 ession in microbial and plant hosts provided proof of concept for metabolic engineering of pseudolara
34             Our findings offer a preclinical proof of concept for small-molecule therapies to target
35 e Golgi organizational states and provides a proof of concept for the classification of drugs and gen
36        Taken together, these results provide proof of concept for the development of liver-targeted m
37                       These findings provide proof of concept for the development of small molecule i
38    Together, our results offer a preclinical proof of concept for the low-dose use of isoform-specifi
39        In this study, we provide preclinical proof of concept for the role of a proinflammatory CXCL1
40 ollectively, our results offer a preclinical proof of concept for the use of anti-Jagged1/2 to reprog
41 ollectively, our results offer a preclinical proof of concept for the use of protein myristoylation i
42 cer cell migration and provide a preclinical proof of concept for their candidacy as targets to treat
43 nction for CD44V6 in lung fibrosis and offer proof of concept for therapeutic targeting of CD44V6 in
44                                          The proof of concept is shown by using polypyrrole (PPy) fil
45                                   This first proof of concept may ultimately be applicable to geofenc
46                              To evaluate the proof of concept of an intervention to teach surgeons to
47                      These results provide a proof of concept of systemic antitumor activity after in
48                            This work shows a proof of concept of the use of monodisperse Si and C nan
49                                          The proof of concept of utilizing a microfluidic dielectroph
50            F6P-biosensor is a very promising proof of concept required for the design of a carbohydra
51                                              Proof of concept studies of tissue phantoms yielded a me
52                                              Proof of concept studies were performed to detect saliva
53                                         This proof of concept study demonstrates that bacterial flora
54                                         This proof of concept study demonstrates that pericardial res
55 ed, allowing for the initiation of a Phase-2 proof of concept study.
56           Our findings provide a preclinical proof of concept supporting the initiation of a clinical
57               Conclusion This study provides proof of concept that a machine learning model can be ap
58                        We have also provided proof of concept that blocking 12-HETE production is a p
59                     These inhibitors provide proof of concept that both sides of DENV protease active
60                           This is a decisive proof of concept that cancer cells' malignant behaviour
61                     These findings provide a proof of concept that introducing gut bacteria to a herb
62                             This study shows proof of concept that LAIVs boost preexisting, cross-rea
63                             Our data provide proof of concept that single-particle EM can be used to
64                                              Proof of concept that such proteins can be detected with
65                      This study is the first proof of concept that targeting a lncRNA to transcriptio
66             Collectively, these data provide proof of concept that targeting thrombin or fibrin(ogen)
67 peutic mechanisms were undefined and in vivo proof of concept was limited.
68                                         As a proof of concept we exposed growing colonies of Escheric
69                                         As a proof of concept, 61,913 protein-protein interactions we
70                                           As proof of concept, a photo-cross-linkable derivative of c
71                                         As a proof of concept, a reversible label-free glutathione-S-
72                                         As a proof of concept, a time resolved fluorescence based san
73                                         As a proof of concept, amplification of a gene specific to a
74 n silicon and transparent glass surfaces: as proof of concept, clusters of either one, two, or three
75                                           As proof of concept, copper(II) in aqueous samples was conv
76                                           As proof of concept, cultured renal epithelial cells were e
77                                           As proof of concept, Fogarty et al. (2017) used CRISPR/Cas9
78                                   Here, as a proof of concept, genetically engineered BLNs, which dis
79 hen deployed on novel experimental data as a proof of concept, illustrating the recruitment of LAT to
80                                Further, as a proof of concept, it is demonstrated that the DNF can de
81 d as the best candidate and to establish the proof of concept, its ability to enhance Neph1-CD and ZO
82                                           As proof of concept, Nd/Sm and Nd/Dy are used as binary mod
83                             As a preclinical proof of concept, specific tumor uptake, pharmacokinetic
84                                         As a proof of concept, the biodistribution of (89)Zr-Df-pembr
85                                         As a proof of concept, the development of dual-membrane-coate
86                                         As a proof of concept, the Janus particle-derived catalyst ca
87                                         As a proof of concept, this approach shows that stochastic mo
88                                           As proof of concept, we apply the theory for the investigat
89                                           As proof of concept, we demonstrate that our mouse model pe
90                                As an initial proof of concept, we developed stepwise multiple linear
91                                         As a proof of concept, we employed sUHR to determine the lipi
92                                      In this proof of concept, we generate and sequence six sciHi-C l
93                               Moreover, as a proof of concept, we include the experimental validation
94                                           As proof of concept, we mutagenized a selected region withi
95                                         As a proof of concept, we performed a biochemical characteriz
96 sing optical sensing of chloramphenicol as a proof of concept, we show here that a GFP variant engine
97                                         As a proof of concept, we target the ACT1 promoter of the mod
98                                         As a proof of concept, we translated our murine data to the t
99                                         As a proof of concept, wild-type (ATCC 29212) and vancomycin-
100 validating these assays and ultimately as a "proof of cure."
101 eferred over others lacking optimization and proof of efficacy and safety.
102 xpressed at high levels within 1 week, and a proof of efficient function analysis is shown using the
103 e the phenotype, and genetic or experimental proof of gain or loss of function in select cases has cl
104 utes to low agonist efficacy, and presents a proof of mechanism that relocating deltaR improves effic
105 e demonstrate the efficacy of our methods in proof of principle experiments and application to real w
106                             Here, we present proof of principle experiments of an optical gating conc
107 ases of engineered gene drives due to recent proof of principle experiments with the CRISPR-Cas9 syst
108                            Here we provide a proof of principle for a novel two-pronged modality refe
109                This study provides the first proof of principle for an epigenetics-based therapy for
110 ully reconstruct the biliary tree, providing proof of principle for organ regeneration using human pr
111                          This study provides proof of principle for the application of targeted next-
112  to act against intracellular Mtb, providing proof of principle for the efficacy of a "release and ki
113                                              Proof of principle for the potential of scanning LC-FAIM
114  replacement for type 1 diabetes and provide proof of principle for therapeutic cloning combined with
115                                              Proof of principle for this therapeutic approach was dem
116                                              Proof of principle of in vivo targeting of human islets
117 vo In summary, this study provides the first proof of principle of small-molecule-mediated interferen
118                                        These proof of principle results open a pathway for directing
119                                            A proof of principle study using F/R incorporated into lip
120               This study provides additional proof of principle that an apelin receptor agonist may b
121                      These results provide a proof of principle that can inform prospective vaccine d
122                            Our work provides proof of principle that chemotherapy paired with an "eco
123       Overall, our studies represent a clear proof of principle that MT-Hec1-interacting compounds ma
124                                  It provides proof of principle that Skp2 targeting is a promising ap
125                                   We provide proof of principle that small molecules that target the
126                         This also provides a proof of principle that suboptimal CD8 T cell in old org
127 CRF-overexpressing (CRF-OE) mice to test the proof of principle that when CRF is in excess, sex-biase
128 sease susceptibility gene and demonstrate in proof of principle the utility of induced neuron-based m
129 in recent years from theoretical to clinical proof of principle with the publication of a first-in-ma
130                                           As proof of principle, a range of different shapes, alignme
131                                         As a proof of principle, a selected reaction monitoring (SRM)
132                                         As a proof of principle, PLSR was used to build soil-bacteriu
133                                         As a proof of principle, we acquired 4D (H)COCANH, (H)CACONH,
134                                           As proof of principle, we apply HiHiMap to measure the leve
135                                           As proof of principle, we apply this approach to interrogat
136                                           As proof of principle, we assembled genomes of the pigeon (
137                                         As a proof of principle, we demonstrate the capability of thi
138                                         As a proof of principle, we demonstrated correlation of the h
139 nting with symptoms of long-QT syndrome as a proof of principle, we demonstrated that commercially av
140                                           As proof of principle, we demonstrated that inactivation of
141                                         As a proof of principle, we predict and measure the gap openi
142                                         As a proof of principle, we used this new "nanomapping" metho
143                                         As a proof of principle, we were able to simultaneously inact
144 miR-430 in developing zebrafish embryos as a proof of principle.
145 ntrary to previous reports, we have found no proof of Rb or K incorporation into the 3D perovskite la
146 rtainty for the Brighton Collaboration, with proof of recent ZIKV infection and negative screening fo
147 ation (3NLSE) domain, and provides a further proof of the computational abilities of the scheme.
148                                           As proof of the concept, the success of the method was demo
149 etical advances, we lack direct experimental proof of the validity of these widely used control princ
150 gnetic properties, we provide an alternative proof of validity of these thermal For each individual s
151 ade of rationally designed DNA molecules are proofs of concept for embedding control within complex m
152        Meanwhile, recent discoveries provide proofs of principle for breakthroughs in a family of res
153                                         This proof-of-concept analysis demonstrates that unsupervised
154                            Here we present a proof-of-concept application for the rational design of
155                                         In a proof-of-concept application in organocatalysis, the dia
156                                         As a proof-of-concept application, the obtained ultrathin COF
157 ative stress mechanisms in TBI and provide a proof-of-concept approach to improve acute TBI managemen
158 e present experimental results comparing two proof-of-concept ballast molecules, and show that the ba
159 scharged MnO2 could be recovered, enabling a proof-of-concept biobattery/supercapacitor hybrid device
160 rst steps have been reported with respect to proof-of-concept cardiovascular therapeutic applications
161 n by ultrasound cavitation was assessed in a proof-of-concept clinical trial in 12 subjects with stab
162 immune system, our results suggest that this proof-of-concept could potentially be utilized to reduce
163           This pilot study provides not only proof-of-concept data on the work impairment collected w
164                                         This proof-of-concept dynamic NA method is an extension of a
165                                         As a proof-of-concept example, we conducted theoretical evalu
166                                          Our proof-of-concept experiments show that multiple desired
167 atient-derived xenografts (zPDX) and provide proof-of-concept experiments that compare response to ch
168                         These data provide a proof-of-concept for a new disease mechanism involving t
169                       This study serves as a proof-of-concept for a new strategy for chemical imaging
170                            We present here a proof-of-concept for bisphenol A detection; the device c
171                  These results contribute to proof-of-concept for enhanced ethanol ablation as a nove
172 rent design considerations are explored, and proof-of-concept for highly pathogen-specific cargo rele
173 calable to microwell formats, and we provide proof-of-concept for its use in testing entry inhibitors
174                          Here, we describe a proof-of-concept for new methodology to detect and quant
175  antitumor efficiency by FF conjugates and a proof-of-concept for new photosensitizer carriers based
176                             Here, we provide proof-of-concept for the TFT, by showing that introducti
177                     Our results constitute a proof-of-concept for, to our knowledge, a new design pri
178                                            A proof-of-concept gas sensor equipped with the resulting
179                  Together these data provide proof-of-concept genetic evidence that blocking the clat
180                                              Proof-of-concept has been established in nonhuman primat
181                               Data from this proof-of-concept implementation is fit by a proposed mod
182                                         In a proof-of-concept in vivo experiment, blockade of C1q and
183  is designed and fabricated to demonstrate a proof-of-concept integrated device, which features wirel
184                     Moreover, to move beyond proof-of-concept into translational applications, we dis
185                                            A proof-of-concept is demonstrated by an immunospecific de
186 tive ion detectors are used to demonstrate a proof-of-concept low-cost, amplifier-free, light-emittin
187                                      Limited proof-of-concept monotherapy studies to evaluate safety
188                   We fabricated and tested a proof-of-concept NanoThermoMechanical device that has sh
189                                         This proof-of-concept of a membrane-free battery has an open
190                                   We provide proof-of-concept of Homo-PROTACs using diverse molecules
191                          These results offer proof-of-concept of how the covalent conjugation of two
192                     These findings represent proof-of-concept of the efficacy and tolerability of ant
193                               We performed a proof-of-concept phase Ib study of ibrutinib monotherapy
194                                 To conduct a proof-of-concept pilot study of a wireless, patient-cent
195                                      In this proof-of-concept pilot study, patients wore wristband pe
196                              Additionally, a proof-of-concept prototype system, which integrates an o
197                                         In a proof-of-concept setting systemic treatment with ustekin
198 ts that potentially influence the host, many proof-of-concept studies have demonstrated causative rol
199      In our recent article, we elaborate our proof-of-concept studies of a mouse/human chimeric IgE a
200  routine care in non-randomised, exploratory proof-of-concept studies.
201 mphasis on mechanistic advances and clinical proof-of-concept studies.
202                                         This proof-of-concept study demonstrates the feasibility of a
203 discovery of gammadelta T cells >30 y ago, a proof-of-concept study has not been done to prove the pr
204                                Overall, this proof-of-concept study illustrates an efficient, general
205                              Conclusion This proof-of-concept study indicates that TA of nonenhanced
206                           Collectively, this proof-of-concept study links urine peptidomics to molecu
207 of the peripheral nervous system in MS, this proof-of-concept study may offer new insights into the p
208                                         This proof-of-concept study provides a new direction for regu
209                                         This proof-of-concept study sheds light on genotype-phenotype
210                                         This proof-of-concept study shows that the development of bot
211                                            A proof-of-concept study was conducted using T2 bacterioph
212 sed on a meta-Lasso regression model and the proof-of-concept study was performed using a large-scale
213                                      In this proof-of-concept study, Raman microspectroscopy was util
214                                      In this proof-of-concept study, stable isotope probing (SIP) was
215                                         In a proof-of-concept study, we defined two groups (1) an acu
216                                         In a proof-of-concept study, we enrolled 10 patients with lun
217                                         In a proof-of-concept study, we previously showed that colore
218  percutaneous nephrolithotomy (PCNL) in this proof-of-concept study.
219                  In this study, we present a proof-of-concept technology comprising an on-chip planar
220 n actin polymerization in vitro As a further proof-of-concept test for cellular effects of these comp
221                               We establish a proof-of-concept that a microtubule motor-cargo interfac
222                                              Proof-of-concept that FFLUX's architecture is suitable f
223            Ultimately, our work demonstrates proof-of-concept that lentiviruses can be used for perma
224                             Our data provide proof-of-concept that this technology can be used to tre
225 e laws of physics and has rapidly grown from proof-of-concept to robust demonstrations and deployment
226 , single-blind, randomised, sham-controlled, proof-of-concept trial.
227 d timing studies when rushing from promising proof-of-concept trials with surrogate end points such a
228                  In this paper, we present a proof-of-concept validation experiment on top-view image
229                                           As proof-of-concept we investigated proteome-wide protein i
230                                 Herein, as a proof-of-concept, a family of dendrimers displaying inte
231                                           As proof-of-concept, a prototype platform is successfully u
232                                         As a proof-of-concept, the ability of niosomes to prevent phy
233                                         As a proof-of-concept, these materials were fabricated into t
234                                         As a proof-of-concept, this study demonstrates the successful
235                          In addition to this proof-of-concept, use of PR scaffolds with differing phy
236 ancies have demonstrated compelling clinical proof-of-concept, validating the biology and drug discov
237                                           As proof-of-concept, we carry out field demonstrations wher
238                                         As a proof-of-concept, we delivered short guide RNAs targetin
239                                         As a proof-of-concept, we demonstrate the application of the
240                  Using ABO blood typing as a proof-of-concept, we developed i) an integrated biologic
241                                         As a proof-of-concept, we have subjected the fourth generatio
242                                          For proof-of-concept, we propose an oxide-semiconductor-oxid
243                                As an initial proof-of-concept, we used antibody-peptide fusions and f
244                                         As a proof-of-concept, we used these advances to rapidly muta
245                                           As proof-of-concept, we used this technology to treat mouse
246  validated the top 2 candidates in vivo as a proof-of-concept.
247 rst tested on a three-compartment phantom as proof-of-concept.
248 enhagen for the years 2016-2030 is used as a proof-of-concept.
249 ous targets, the progress on translating the proof-of-concepts to commercially viable and environment
250 istic 1,000 and 6,000 muatm exposures, and a proof-of-principle 30,000 muatm exposure.
251                               We highlight a proof-of-principle and describe the working principle fo
252 me analysis by nanoLC-MS(2), and demonstrate proof-of-principle applications of the duplex and triple
253             Using this network, we perform a proof-of-principle demonstration of QDS mediated by MDI-
254                           These data provide proof-of-principle evidence for the therapeutic potentia
255                  Finally, we provide several proof-of-principle examples in which we model the effect
256                                         In a proof-of-principle experiment, treatment of these two su
257                                         This proof-of-principle experimental system allowed us to qua
258                                              Proof-of-principle experiments demonstrated that in a ce
259                                        These proof-of-principle experiments show that the combination
260                                           In proof-of-principle experiments, we manipulated apterous,
261              In this article, we establish a proof-of-principle for methods to initiate and then moni
262                           These data provide proof-of-principle for the view that newly generated ASC
263 nolysis of alpha-pinene has been chosen as a proof-of-principle model system.
264 on, gastric inhibitory polypeptide (GIP), as proof-of-principle peptides to demonstrate the value of
265                               Based on these proof-of-principle results in healthy individuals, we pr
266                                         This proof-of-principle shows that specific enrichment of ele
267 ne therapy using AAV vectors and showed in a proof-of-principle study how this virus-host interaction
268                                          Our proof-of-principle study illustrates that transcriptome-
269                                         This proof-of-principle study introduces a sensing mechanism
270                          In this physiologic proof-of-principle study, we determined whether transfus
271                To test this concept, in this-proof-of-principle study, we screened for modulators of
272                                       In our proof-of-principle study, we used comparative flow cytom
273  providing an excellent starting point for a proof-of-principle study.
274                          Notably, we provide proof-of-principle that inhibiting IP3R3 degradation in
275 odels and human material provide preclinical proof-of-principle that validates uPA as a novel therape
276                                     We did a proof-of-principle trial with a novel endovascular baror
277 tis undergoing total knee replacement into a proof-of-principle trial.
278                                   We provide proof-of-principle under seminatural conditions for two
279                                 As our first proof-of-principle we employed the bacterial chemotaxis
280                                           As proof-of-principle, cell viability and immune responses
281                                         As a proof-of-principle, deoxynivalenol (DON), an important m
282                                         As a proof-of-principle, fluorophores containing a borinate (
283         In summary, these findings provide a proof-of-principle, rational strategy to target the MYB
284                                          For proof-of-principle, the clinically relevant glucagon-lik
285                                           As proof-of-principle, we conducted large-scale cell cycle
286                                         As a proof-of-principle, we explore the interactions of S. ce
287                               To demonstrate proof-of-principle, we used the TRBO-sgRNA delivery plat
288 clinical studies have demonstrated promising proofs-of-concept, the performance of human clinical BCI
289  all exhibiting high R(2) values, serve as a proof-on-concept for the use of metabolic data for the d
290    Mutations of this motif directly modulate proof-reading by eliminating or enhancing selectivity fo
291                Here, we directly monitor RNA proof-reading by RIG-I and we show that it is controlled
292      It has been suggested that RIG-I has a 'proof-reading' mechanism for rejecting host RNA targets,
293                               [Note added in proof: Since the writing of this article, a fourth biosi
294                 Criminal convictions require proof that a prohibited act was performed in a statutori
295           In this work, we sought definitive proof that dicarboxylic acids are produced in diesel eng
296 s to promote phenotype switching and provide proof that targeting tumour cell plasticity is a viable
297  and then asthma, there is yet no definitive proof that the atopic march is the primary causal factor
298 icroorganism is commonly used in industry to proof the sterilization efficiency.
299 41 SSNs confirmed with surgically pathologic proof were retrospectively reviewed.
300          This work presents the experimental proof which validates the hypothesis of a pH change duri

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top